Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-023-04592-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Sabin Goktas Aydin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, TEM Avrupa Otoyolu Goztepe, Cikisi, No: 1, Bagcilar, 34214, Istanbul, T…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androstenes, Benzamides, Phenylthiohydantoin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic biomarkers have been identified in CRPC, the significance of serum inflammatory markers remains unclear. MATERIALS AND METHODS: This retrospective study included 79 CRPC patients treated with abiraterone or enzalutamide. Inflammatory markers, including the modified Glasgow prognostic score (mGPS), systemic immune-inflammation index (SII), and neutrophil-to-lymphocyte ratio (NLR), were assessed as predictive tools for treatment response. Patient data were obtained from medical charts, and statistical analyses were performed. RESULTS: The median age of the patients was 67 years, with most having a Gleason score of 8-10. The median values for NLR, PLR, and SII were 2.9, 168.5, and 713.5, respectively. The objective response rate (ORR) to abiraterone or enzalutamide therapy was 55.1%. mGPS showed a significant association with ORR, with the mGPS 0 group having the highest response rate (59.5%). Median progression-free survival (PFS) was 12.8 months, and median overall survival (OS) was 35.4 months. Palliative radiotherapy during therapy and PSA doubling time were independent prognostic factors for PFS. CONCLUSIONS: mGPS and PSA doubling time significantly impacted survival, and mGPS significantly predicted the treatment response in mCRPC, which may lead to further prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, TEM Avrupa Otoyolu Goztepe, Cikisi, No: 1, Bagcilar, 34214, Istanbul, Turkey. drsabingoktas@gmail.com.
- Medical Faculty, Department of Medical Oncology, Istanbul Medipol University, TEM Avrupa Otoyolu Goztepe, Cikisi, No: 1, Bagcilar, 34214, Istanbul, Turkey.
- Medical Faculty, Department of Internal Medicine, Istanbul Medipol University, TEM Avrupa Otoyolu Goztepe, Cikisi, No: 1, Bagcilar, 34214, Istanbul, Turkey.
ORCID-Profile: Sabin Goktas Aydin
Zitieren
APA
Goktas Aydin, S., Kutlu, Y., Muglu, H., Aydin, A., Acikgoz, O., Hamdard, J., Karci, E., Bilici, A., Olmez, O. F., & Yildiz, O. (2024). Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04592-x
Vancouver
Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz O, Hamdard J, et al. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-023-04592-x
BibTeX
@article{GoktasAydin2024,
author = {Goktas Aydin, Sabin and Kutlu, Yasin and Muglu, Harun and Aydin, Ahmet and Acikgoz, Ozgur and Hamdard, Jamshid and Karci, Ebru and Bilici, Ahmet and Olmez, Omer Fatih and Yildiz, Ozcan},
title = {Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-023-04592-x}
}
EUVIMED